Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder (MDD).
According to an analysis by William Blair, the data regarding XENE1101's efficacy signals support its future development in Major Depressive Disorder (MDD). Despite a notable 13.9-point improvement on the MADRS scale for the placebo at week 6, the primary efficacy result was somewhat obscured, underscoring the complexity of treating depression.
The high ...